Oral Edaravone - Introducing a Flexible Treatment Option for Amyotrophic Lateral Sclerosis

Area of Science:

• Neuroscience
• Pharmacology
• Clinical Trials

Background:

• Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease with limited therapeutic options.
• The U.S. Food and Drug Administration (FDA) approved intravenous (IV) edaravone in 2017 and oral edaravone in 2022 for ALS treatment.

Purpose of the Study:

• To review the pharmacokinetics, pharmacodynamics, safety, and efficacy of oral edaravone.
• To discuss the clinical profile and development program of oral edaravone.
• To summarize findings from completed and ongoing clinical trials.

Main Methods:

• Literature review utilizing PubMed.gov from the US National Library of Medicine.
• Analysis of published data on oral edaravone's clinical profile.
• Inclusion of data from the oral edaravone clinical trial development program.

Main Results:

• Edaravone has demonstrated efficacy in slowing the rate of motor function deterioration in ALS patients.
• The oral formulation provides a convenient administration route for patients.
• Ongoing research and real-world evidence are expanding the understanding of oral edaravone's clinical utility.

Conclusions:

• Oral edaravone represents a significant advancement in ALS pharmacotherapy.
• Patients can now exclusively use oral medications for ALS treatment.
• Further research is essential to fully elucidate the long-term clinical profile and benefits of oral edaravone.